[go: up one dir, main page]

MX2020001812A - Formulaciones nanoestructuradas para el suministro de silibinina y otros ingredientes activos para tratar enfermedades oculares. - Google Patents

Formulaciones nanoestructuradas para el suministro de silibinina y otros ingredientes activos para tratar enfermedades oculares.

Info

Publication number
MX2020001812A
MX2020001812A MX2020001812A MX2020001812A MX2020001812A MX 2020001812 A MX2020001812 A MX 2020001812A MX 2020001812 A MX2020001812 A MX 2020001812A MX 2020001812 A MX2020001812 A MX 2020001812A MX 2020001812 A MX2020001812 A MX 2020001812A
Authority
MX
Mexico
Prior art keywords
active ingredients
eye diseases
silibinin
supply
treat eye
Prior art date
Application number
MX2020001812A
Other languages
English (en)
Other versions
MX388310B (es
Inventor
Anna Rita Blanco
Maria Luisa Bondi'
Gennara Cavallaro
Grazia Maria Letizia Consoli
Gaetano Giammona
Emanuela Fabiola Craparo
Mariano Licciardi
Giovanna Pitarresi
Giuseppe Granata
Patrizia Saladino
Marca Clara La
Irene Deidda
Salvatore Papasergi
Salvatore Cuzzocrea
Santa Viola
Patrizia Guarneri
Emanuela Esposito
Original Assignee
Distretto Tecnologico Sicilia Micro E Nano Sistemi S C A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Distretto Tecnologico Sicilia Micro E Nano Sistemi S C A R L filed Critical Distretto Tecnologico Sicilia Micro E Nano Sistemi S C A R L
Publication of MX2020001812A publication Critical patent/MX2020001812A/es
Publication of MX388310B publication Critical patent/MX388310B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/92—Systems containing at least three condensed rings with a condensed ring system consisting of at least two mutually uncondensed aromatic ring systems, linked by an annular structure formed by carbon chains on non-adjacent positions of the aromatic system, e.g. cyclophanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen las formulaciones que contienen silibinina u otros ingredientes activos incorporados en los sistemas de nanopartículas de lípidos del tipo SLN y NLC, y se basan en calixarenos, posiblemente mucoadhesivos o en sistemas micelares y de nanopartículas con base en copolímeros de inulina anfifílicos para uso en el tratamiento de enfermedades oculares neurodegenerativas, la versatilidad del compuesto de calixareno también se describe, capaz de cargar y liberar los ingredientes activos caracterizados para baja solubilidad en agua, fácil degradación química y enzimática, baja biodisponibilidad, ya sea de origen natural o no, para usarse en el tratamiento de enfermedades oculares.
MX2020001812A 2014-10-09 2015-10-09 Formulaciones nanoestructuradas para el suministro de silibinina y otros ingredientes activos para tratar enfermedades oculares MX388310B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITFI20140230 2014-10-09
PCT/IB2015/057732 WO2016055976A1 (en) 2014-10-09 2015-10-09 Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases

Publications (2)

Publication Number Publication Date
MX2020001812A true MX2020001812A (es) 2021-11-30
MX388310B MX388310B (es) 2025-03-19

Family

ID=52444403

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004649A MX2017004649A (es) 2014-10-09 2015-10-09 Formulaciones nanoestructuradas para el suministro de silibinina y otros ingredientes activos para tratar enfermedades oculares.
MX2020001812A MX388310B (es) 2014-10-09 2015-10-09 Formulaciones nanoestructuradas para el suministro de silibinina y otros ingredientes activos para tratar enfermedades oculares

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017004649A MX2017004649A (es) 2014-10-09 2015-10-09 Formulaciones nanoestructuradas para el suministro de silibinina y otros ingredientes activos para tratar enfermedades oculares.

Country Status (14)

Country Link
US (3) US11266659B2 (es)
EP (2) EP3587392B1 (es)
JP (1) JP6744862B2 (es)
CN (3) CN106999427A (es)
AU (2) AU2015329609B2 (es)
BR (1) BR112017006918A2 (es)
CA (1) CA2963872C (es)
ES (2) ES2905458T3 (es)
IL (2) IL251555B (es)
MX (2) MX2017004649A (es)
PL (1) PL3203989T3 (es)
RU (2) RU2726193C2 (es)
SA (1) SA521420975B1 (es)
WO (1) WO2016055976A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999427A (zh) * 2014-10-09 2017-08-01 西西里微纳米系统技术区有限责任合作公司 用于治疗眼部疾病的用于递送水飞蓟宾和其他活性成分的纳米结构化制剂
US11918659B2 (en) 2018-09-20 2024-03-05 University Of Miami Materials and methods for inducing therapeutic hypothermia in a mammalian subject
CN112022848B (zh) * 2020-08-13 2022-02-22 中南大学湘雅二医院 索拉非尼在治疗1型糖尿病中的应用
CN116999431B (zh) * 2023-08-10 2025-05-23 中山大学中山眼科中心 水飞蓟宾在制备预防和/或治疗增殖性玻璃体视网膜病变药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE60133550T2 (de) * 2001-09-17 2009-04-02 Nanopart-C S.A. Neue dispergierbare kolloidale Calixarene-Systeme in Form von Nanoteilchen
ITMI20022323A1 (it) * 2002-10-31 2004-05-01 Maria Rosa Gasco Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
EP2380872B1 (en) 2004-06-15 2014-04-23 Cellceutix Corporation Polycationic compounds and uses thereof
FR2899900A1 (fr) 2006-04-18 2007-10-19 Centre Nat Rech Scient Derives de calixarenes comme agent anticancereux
US20070298069A1 (en) * 2006-06-26 2007-12-27 Boston Scientific Scimed, Inc. Medical devices for release of low solubility therapeutic agents
US8252954B2 (en) 2007-06-07 2012-08-28 The Curators Of The University Of Missouri Processes for the preparation of calixarene derivatives
KR101435242B1 (ko) * 2007-11-15 2014-08-29 마다우스 게엠베하 간염치료용 실리비닌 성분
CN101627970A (zh) * 2008-07-17 2010-01-20 北京北大维信生物科技有限公司 一种药物固体脂质纳米颗粒的制备方法
EP2156834A1 (en) 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CN101554371A (zh) * 2009-04-13 2009-10-14 中国药科大学 水飞蓟宾和水飞蓟素聚合物胶束的制备和应用
CN101632638B (zh) * 2009-08-21 2011-04-20 山东大学 一种水飞蓟宾纳米脂质载体及其制备方法
EP2726057A1 (en) 2011-06-28 2014-05-07 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing sorafenib
CN102949344A (zh) 2011-08-30 2013-03-06 同济大学 一种姜黄素固体脂质纳米粒作为治疗哮喘药物的应用
MX367074B (es) * 2012-01-20 2019-08-05 South Dakota State Univ Inulina y formulaciones de acetato de inulina.
US9707186B2 (en) * 2012-02-21 2017-07-18 Amrita Vishwa Vidyapeetham Core-shell particle formulation for delivering multiple therapeutic agents
NZ742004A (en) * 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
US20150272992A1 (en) * 2012-10-24 2015-10-01 The Texas A&M University System Treatment of Tumors with Activated Mesenchymal Stem Cells
US20160074321A1 (en) * 2013-03-27 2016-03-17 Comprehensive Drug Enterprises, Ltd. Ophthalmic composition, method for preparing the same, and use of the same
CN103655519A (zh) * 2013-12-24 2014-03-26 哈尔滨医科大学 一种具有P-gp抑制作用的姜黄素固体脂质纳米粒及制备方法
CN103655214A (zh) 2013-12-27 2014-03-26 苏州纳康生物科技有限公司 负载四氢姜黄素的纳米载体及其制备方法
CN103784421B (zh) * 2014-02-27 2016-04-27 哈尔滨医科大学 载姜黄素和胡椒碱的固体脂质纳米粒及其制备方法
CN106999427A (zh) * 2014-10-09 2017-08-01 西西里微纳米系统技术区有限责任合作公司 用于治疗眼部疾病的用于递送水飞蓟宾和其他活性成分的纳米结构化制剂

Also Published As

Publication number Publication date
EP3587392A8 (en) 2020-05-27
US20210046083A1 (en) 2021-02-18
RU2017115575A (ru) 2018-11-13
CA2963872C (en) 2023-09-12
AU2021202374A1 (en) 2021-05-13
IL270159B (en) 2021-03-25
IL251555A0 (en) 2017-05-29
IL251555B (en) 2020-07-30
CN106999427A (zh) 2017-08-01
CA2963872A1 (en) 2016-04-14
SA521420975B1 (ar) 2023-12-25
EP3203989B1 (en) 2019-08-21
EP3587392A1 (en) 2020-01-01
MX2017004649A (es) 2017-11-30
EP3587392B1 (en) 2021-11-03
US11253526B2 (en) 2022-02-22
US20220031614A1 (en) 2022-02-03
PL3203989T3 (pl) 2020-06-29
CN112022807A (zh) 2020-12-04
AU2015329609A1 (en) 2017-05-25
US20170216309A1 (en) 2017-08-03
BR112017006918A2 (pt) 2017-12-12
ES2756752T3 (es) 2020-04-27
JP2017530989A (ja) 2017-10-19
WO2016055976A1 (en) 2016-04-14
EP3203989A1 (en) 2017-08-16
RU2726193C2 (ru) 2020-07-09
US11633356B2 (en) 2023-04-25
US11266659B2 (en) 2022-03-08
AU2021202374B2 (en) 2022-12-01
CN112022808A (zh) 2020-12-04
ES2905458T3 (es) 2022-04-08
AU2015329609B2 (en) 2021-01-21
RU2017115575A3 (es) 2019-07-17
JP6744862B2 (ja) 2020-08-19
MX388310B (es) 2025-03-19
RU2019134423A (ru) 2019-11-19

Similar Documents

Publication Publication Date Title
CL2019000575A1 (es) Análogos de amilina.
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
MX2021009673A (es) Moduladores de ror-gamma.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
NI201500167A (es) Compuestos químicos
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
ECSP15014941A (es) Compuestos antivíricos para el vsr
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
NI201500096A (es) Compuesto químicos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2016014411A (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf.
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
MX2016010169A (es) Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
MX2020001812A (es) Formulaciones nanoestructuradas para el suministro de silibinina y otros ingredientes activos para tratar enfermedades oculares.
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
CL2015000608A1 (es) Formulaciones de daptomicina y usos de la misma
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
AR106364A1 (es) Derivados de insulina y sus usos médicos
CL2017000120A1 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.